Agentix Corp. (AGTX) stock
AGTXOTCBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
$0.02+0.00 (0.00%)
Close on Oct 16, 2026Market cap $801.34KP/E –Yield –
Agentix operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Agentix's operating income for the twelve months ending Jun 30, 2026 was -$340.35K. For fiscal 2026 it was -$445.19K. The highest annual figure on record is -$121.32K in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$445.19K | – |
| FY2025 | Mar 31, 2025 | -$513.25K | – |
| FY2024 | Mar 31, 2024 | -$744.81K | – |
| FY2021 | Aug 31, 2021 | -$1.34M | – |
| FY2019 | Aug 31, 2019 | -$121.32K | – |
| FY2018 | Aug 31, 2018 | -$134.38K | – |
| FY2017 | Aug 31, 2017 | -$333.99K | – |
| FY2016 | Aug 31, 2016 | -$292.43K | – |
| FY2015 | Aug 31, 2015 | -$175.13K | – |
| FY2014 | Aug 31, 2014 | -$208.88K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -$95.50K | – |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -$54.29K | – |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$67.46K | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -$123.10K | – |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -$200.34K | – |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -$172.12K | -779.6% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$96.82K | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -$93.01K | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -$151.31K | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $25.33K | – |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -$15.85K | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -$353.16K | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -$401.14K | – |
| Q4 FY2021CQ3 2021 | Aug 31, 2021 | -$243.43K | – |
| Q3 FY2021CQ2 2021 | May 31, 2021 | -$173.24K | – |
| Q2 FY2021CQ1 2021 | Feb 28, 2021 | -$707.07K | – |
| Q1 FY2021CQ4 2020 | Nov 30, 2020 | -$216.72K | – |
| Q3 FY2020CQ2 2020 | May 31, 2020 | -$1.29M | – |
| Q2 FY2020CQ1 2020 | Feb 29, 2020 | -$11.80K | – |
| Q1 FY2020CQ4 2019 | Nov 30, 2019 | -$5.03K | – |
| Q4 FY2019CQ3 2019 | Aug 31, 2019 | -$12.03K | – |
| Q3 FY2019CQ2 2019 | May 31, 2019 | -$30.45K | – |
| Q2 FY2019CQ1 2019 | Feb 28, 2019 | -$35.84K | – |
| Q1 FY2019CQ4 2018 | Nov 30, 2018 | -$43.00K | – |
| Q4 FY2018CQ3 2018 | Aug 31, 2018 | -$28.78K | – |
| Q3 FY2018CQ2 2018 | May 31, 2018 | -$38.90K | – |
| Q2 FY2018CQ1 2018 | Feb 28, 2018 | -$41.02K | – |
| Q1 FY2018CQ4 2017 | Nov 30, 2017 | -$25.68K | – |
| Q4 FY2017CQ3 2017 | Aug 31, 2017 | -$50.60K | – |
| Q3 FY2017CQ2 2017 | May 31, 2017 | -$64.55K | – |
| Q2 FY2017CQ1 2017 | Feb 28, 2017 | -$127.06K | -37036.6% |
| Q1 FY2017CQ4 2016 | Nov 30, 2016 | -$91.78K | – |
| Q4 FY2016CQ3 2016 | Aug 31, 2016 | -$116.20K | – |
| Q3 FY2016CQ2 2016 | May 31, 2016 | -$176.23K | – |
| Q2 FY2016CQ1 2016 | Feb 29, 2016 | $344 | – |
| Q1 FY2016CQ4 2015 | Nov 30, 2015 | -$349 | – |
| Q4 FY2015CQ3 2015 | Aug 31, 2015 | -$25.06K | – |
| Q3 FY2015CQ2 2015 | May 31, 2015 | -$15.26K | – |
| Q2 FY2015CQ1 2015 | Feb 28, 2015 | -$76.70K | – |
See a number that looks wrong?